Kura Oncology (KURA) Long-Term Debt Repayments (2018 - 2021)

Kura Oncology (KURA) reported Long-Term Debt Repayments of $6.5 million for Q2 2021, up 766.67% quarter-over-quarter from $750000.0 in Q1 2021.

Kura Oncology (KURA) Long-Term Debt Repayments (2018 - 2021) Analysis & Trends

Kura Oncology (KURA) has 2 years of Long-Term Debt Repayments data on file, last reported at $6.5 million in Q2 2021.

Long-Term Debt Repayments for Q2 2021 came in at $6.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2021 was $7.2 million (changed N/A YoY), and the FY2021 annual result was $7.2 million, up 2800.0% from the prior year.
Long-Term Debt Repayments climbed to $6.5 million in Q2 2021 per KURA's latest filing, from $750000.0 in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $6.5 million in Q2 2021 and troughed at $250000.0 in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-21,671.00
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Kura Oncology	883.44 Mn	883.44 Mn	18.00 Mn	-

Download Data